Immuno-Oncology | Specialty

Check Point Inhibition in Muscle-Invasive Bladder Cancer

June 1st 2016

Neoadjuvant Therapy in Muscle-Invasive Bladder Cancer

June 1st 2016

First-Line Options in Muscle-Invasive Bladder Cancer

June 1st 2016

Abiraterone Plus Prednisone in CRPC: Factors to Consider

June 1st 2016

CRPC: Patient Selection in AR-Directed Therapies

June 1st 2016

Therapeutic Options in Metastatic CRPC

June 1st 2016

Safety of Low-Dose Steroids with Abiraterone in Prostate Cancer

June 1st 2016

Potential Predictive Markers in Prostate Cancer

June 1st 2016

Candidacy for Chemotherapy in Oligometastatic Prostate Cancer

June 1st 2016

Local and Systemic Therapeutic Options in Low-Volume Prostate Cancer

June 1st 2016

Combining Radium-223 With Other Therapies in Prostate Cancer

June 1st 2016

Factors Impacting Treatment Approach in Advanced Prostate Cancer

June 1st 2016

Defining Symptomatic in Prostate Cancer

June 1st 2016

Treatment of Bone Metastases in Prostate Cancer

June 1st 2016

A Look at This Year's ASCO Pipeline

June 1st 2016

Immunotherapy agents targeting the PD-1/PD-L1 pathway will be the most robust area for news at the 2016 ASCO Annual Meeting, but there will be much new data about recently approved and novel anticancer drugs for clinicians to digest.

CD4 T-Cell Immunotherapy Has Potential in Multiple Tumor Types

May 29th 2016

Yong-Chen William Lu, PhD, discusses a phase I dose-escalation study investigating the genetically engineered CD4 T cells' ability to target the MAGE-A3 protein.

Dr. Keith Keer on PD-L1 in Lung Cancer

May 26th 2016

​Keith Kerr, BSc, MB, ChB, FRCPath, FRCPE, of the University of Aberdeen, Aberdeen, Scotland, discusses PD-L1 immunohistochemistry in lung cancer.

Dr. Lutzker on OX40 Agonist in Patients With Refractory Solid Tumors

May 23rd 2016

Stuart Lutzker, MD, PhD, vice president of BioOncology Exploratory Clinical Development, Genentech, discusses results of the first-in-human study of OX40 agonist in patients with refractory solid tumors.

Dr. Steinberg on the FDA Approval of Atezolizumab in Bladder Cancer

May 19th 2016

Gary D. Steinberg, MD, Bruce and Beth White Family Professor, professor of Surgery, director of Urologic Oncology, University of Chicago Medicine, discusses the FDA approval of atezolizumab (Tecentriq) as a treatment for patients with with locally advanced or metastatic urothelial carcinoma (mUC) whose disease progressed during or after platinum-based chemotherapy, or within 12 months of receiving platinum-containing chemotherapy, either before or after surgery.

Pembrolizumab 3-Year Survival Rate Hits 40% in Melanoma

May 19th 2016

Forty percent of patients with advanced melanoma who started taking pembrolizumab during the clinical trial that led to its initial approval were still alive after 3 years, with many responders in remission even after stopping treatment.